Arrivent Biopharma Inc

NASDAQ:AVBPUnited States

ArriVent Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. Its lead development candidate, Furmonertinib, and advance a pipeline of novel therapeutics, such as antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors. Furmonertinib is an oral, highly brain-penetrant, active mutation-selective EGFR inhibitor that targets both classical (exon 19 deletion and L858R) and uncommon EGFR mutations, including exon 20 insertion mutations, as well as HER2 exon 20 insertion mutations. Furmonertinib is an investigational, novel, EGFR mutant-selective tyrosine kinase inhibitor that is developing for the treatment of NSCLC patients across a set of EGFR mutations. It is also focused on development and commercialization of the ARR-002 program.

Contact Information

Headquarters

18 Campus Blvd., Suite 100NEWTOWN SQUARE, PA, United States 19073-3269

Phone

240-780-6356

Fax

302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer

Zhengbin Yao

Chief Financial Officer, Treasurer

Winston Kung

Chief Operating Officer

Robin Lachapelle

Chief Technology Officer

Yang Wang

General Counsel, Secretary

James Kastenmayer